264) but was too large for practical clinical use. |
265) ld accounting for almost 70% of the water use. |
266) intuitive functions and were difficult to use. |
267) es may still be barriers to their optimal use. |
268) aytime function, and increase health care use. |
269) ory were homicide, suicide, and substance use. |
270) sis are rapidly progressing into clinical use. |
271) e adverse events secondary to epinephrine use. |
272) still no gold-standard PROM in widespread use. |
273) s shows what equipment they are likely to use. |
274) r intended for clinical and translational use. |
275) an attention to equity in UGS access and use. |
276) s/motivational factors for fitness centre use. |
277) ment and electronic services (e-services) use. |
278) hical setting, emission sources, and land use. |
279) ttings but is not validated for community use. |
280) d provide recommendations on their future use. |
281) decrease opioids in patients with chronic use. |
282) challenges and lessons learned from their use. |
283) on the ethical challenges surrounding its use. |
284) predict the potential for methamphetamine use. |
285) of their biases of terminology and syntax use. |
286) one aspect of that environment, headphone use. |
287) nsitivity and low reliability limit their use. |
288) We then use the BinomiRare test to test the associ |
289) er, individuals with mental illness often use the Emergency Department as a primary |
290) We use the Human Leukocyte Antigen (HLA) locu |
291) Methods and Analysis: We will use the Joanna Briggs Institute framework |
292) uded any clear recommendations on when to use the TSP, or if it should be used at al |
293) en developed for this situation, where we use the available IPD to adjust for betwee |
294) In the second stage, we use the baseline risk score from the first |
295) Factor analysis models use the covariance of measured variables t |
296) Additionally, we use the data from the greenhouse experimen |
|